Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
IDWeek: Ending HIV as an epidemic will demand innovation, inclusion, an expanded workforce — and funding
As the federal Ending the HIV epidemic takes form, experts talk details, challenges: “How do we get there from here?” WASHINGTON, DC – Nearly four decades […]
But with a $3.3 billion shortfall in funding, gaps in treatment and prevention among the most vulnerable still take 4,000 lives a day For the first […]
While a World Health Organization-led strategy aims to provide 1.4 billion doses of vaccine against yellow fever to achieve 80% vaccination coverage across countries by 2026 […]
The following is a guest post By Sharon Weir, Ph.D. of MEASURE Evaluation The Priorities for Local AIDS Control Efforts — PLACE –method aims to improve […]